133 related articles for article (PubMed ID: 15579494)
21. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
22. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
[TBL] [Abstract][Full Text] [Related]
23. Isolation of a murine metastatic cell line and preliminary test of sensitivity to the anti-metastasis agent NAMI-A.
Pacor S; Vadori M; Vita F; Bacac M; Soranzo MR; Zabucchi G; Sava G
Anticancer Res; 2001; 21(4A):2523-30. PubMed ID: 11724317
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
25. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
26. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
Pintus G; Tadolini B; Posadino AM; Sanna B; Debidda M; Bennardini F; Sava G; Ventura C
Eur J Biochem; 2002 Dec; 269(23):5861-70. PubMed ID: 12444974
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.
Pacor S; Zorzet S; Cocchietto M; Bacac M; Vadori M; Turrin C; Gava B; Castellarin A; Sava G
J Pharmacol Exp Ther; 2004 Aug; 310(2):737-44. PubMed ID: 15075381
[TBL] [Abstract][Full Text] [Related]
29. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
Chen J; Chen L; Liao S; Zheng K; Ji L
J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
[TBL] [Abstract][Full Text] [Related]
30. Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.
Vadori M; Pacor S; Vita F; Zorzet S; Cocchietto M; Sava G
J Inorg Biochem; 2013 Jan; 118():21-7. PubMed ID: 23123335
[TBL] [Abstract][Full Text] [Related]
31. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
32. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
Sava G; Gagliardi R; Bergamo A; Alessio E; Mestroni G
Anticancer Res; 1999; 19(2A):969-72. PubMed ID: 10368640
[TBL] [Abstract][Full Text] [Related]
33. The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.
Vadori M; Florio C; Groppo B; Cocchietto M; Pacor S; Zorzet S; Candussio L; Sava G
J Biol Inorg Chem; 2015 Jul; 20(5):831-40. PubMed ID: 25982099
[TBL] [Abstract][Full Text] [Related]
34. The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.
Guidi F; Modesti A; Landini I; Nobili S; Mini E; Bini L; Puglia M; Casini A; Dyson PJ; Gabbiani C; Messori L
J Inorg Biochem; 2013 Jan; 118():94-9. PubMed ID: 23142974
[TBL] [Abstract][Full Text] [Related]
35. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling.
Zhou J; Chen Y; Lang JY; Lu JJ; Ding J
Mol Cancer Res; 2008 Feb; 6(2):194-204. PubMed ID: 18314480
[TBL] [Abstract][Full Text] [Related]
36. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
37. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
[TBL] [Abstract][Full Text] [Related]
38. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
[TBL] [Abstract][Full Text] [Related]
39. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
